Liquidia (NASDAQ:LQDA) Director Arthur Kirsch Sells 10,000 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Arthur Kirsch sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $54.80, for a total transaction of $548,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Liquidia Trading Up 0.8%

Shares of NASDAQ:LQDA opened at $55.53 on Thursday. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $63.46. The business has a 50 day moving average of $45.73 and a 200-day moving average of $39.16. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The stock has a market cap of $4.94 billion, a PE ratio of 396.66 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The company’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, equities research analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on LQDA shares. Wells Fargo & Company increased their price target on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research note on Thursday, March 5th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Oppenheimer raised their price objective on shares of Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a report on Thursday, March 12th. Finally, HC Wainwright raised their price objective on shares of Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the 4th quarter worth approximately $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at about $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia in the 3rd quarter valued at about $34,000. Finally, Covestor Ltd lifted its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).